ClinicalTrials.gg
CompletedNCT02674386Updated Jul 30, 2020Results posted

Long-term Observational Study of Subjects From Tanezumab Studies Who Undergo a Total Knee, Hip or Shoulder Replacement

A Phase 3 interventional study of Investigational Medical Product (IMP) administered in parent study in Osteoarthritis, sponsored by Pfizer. Completed at 79 sites in 15 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-07-30.

Sponsored by Pfizer · Phase 3, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
154
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 39 studies in Osteoarthritis by Pfizer — 2 open to participants now, 2 under way, 2 of them phase 3. Osteoarthritis · Pfizer.

Enrollment
25th of 37
154 · median 265
Started
2016
with 1 other
Phase 3
21 of 39
2 open now
Registered
35th of 39
by date

Among the 39 studies in Osteoarthritis by Pfizer, this one is the 25th largest by enrollment of the 37 interventional ones that give a count, is one of 2 that started in 2016, is one of 21 in phase 3, and was the 35th registered.

Osteoarthritis

2,975 studies on the registry are indexed under Osteoarthritis; 436 are open to participants now.

Browse Osteoarthritis studies →

Open to participants now

2 of the 39 studies in Osteoarthritis by Pfizer are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 285 Osteoarthritis studies recruiting now, 157 (55%) set no upper age limit and 71 (25%) stop at 75 or younger; 22 take children under 18; 30 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies in Osteoarthritis by Pfizer, or all of them as a file.
02

Study summary

A4091064 is a multicenter, long-term observational study of subjects from tanezumab interventional studies (regardless of treatment group) who undergo a total knee, hip or shoulder replacement during participation in the study. The study is designed with a total duration of subject follow-up of 24 weeks after the total joint replacement surgery. There will be two methods of data collection utilized in this study: interview by site staff via the telephone and interactive web-response system (or paper if the subject has no access to the internet).

Read the detailed description

A4091064 is a long-term observational follow up study of subjects from tanezumab interventional studies A4091056, A4091057 or A4091058.

03

Conditions studied

  • Osteoarthritis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Personally signed and dated document.
  • Randomized and treated with subcutaneous product in a tanezumab study and has completed the study or been withdrawn from the study.
  • Actual or planned total knee, hip or shoulder replacement surgery during the tanezumab study.
  • Willing and able to comply with scheduled visits and other study procedures.

Exclusion criteria

Exclusion Criteria:

  • None.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
154 participants (actual)

Study arms

  • Other
    Cohort 1

    long-term observational study of subjects from tanezumab parent study

    Drug: Investigational Medical Product (IMP) administered in parent study

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Surgeon's Assessment of Procedural Difficulty

    Following the TJR surgery on Day 1, the orthopedic surgeon was asked to answer the following question: "taking into consideration the participant's medical history and physical condition prior to surgery would you classify the operative procedure as Uneventful, Minor complications or Major complications." Participants were reported based on these categories for knee, hip and shoulder joint. Participants may have been counted more than once if they had TJR surgery in more than one joint.

    Time frame: Day 1

  2. Number of Participants With Overall Satisfaction With Surgery as Assessed by the Self-Administered Patient Satisfaction (SAPS) Scale at Week 24

    SAPS contained four questions; How satisfied are you with the 1) results of your surgery 2) results of surgery for improving pain 3) results of surgery for improving ability to do home or yard work, and 4) results of surgery for improving your ability to do recreational activities. Items scored on a 4-point Likert scale with response of 'very satisfied' (100 points), 'somewhat satisfied' (75 points), 'somewhat dissatisfied' (50 points), and 'very dissatisfied' (25 points). The scale score calculated as mean of the scores of individual items, ranging from 25 to 100, with higher scores indicating greater satisfaction. Here, number of participants are summarized as, satisfied (very satisfied and somewhat satisfied categories combined) and dissatisfied (somewhat dissatisfied and very dissatisfied categories combined). Participants may have been counted more than once if they had TJR surgery in more than one joint.

    Time frame: Week 24

  3. Number of Participants With Post-Surgical Complications Upto Week 24

    Post-surgical complications are adverse events occurring after TJR surgery that were considered clinically significant as assessed by investigator and attributable to the total joint replacement procedure. Participants may have been counted more than once if they had TJR surgery in more than one joint.

    Time frame: Baseline up to Week 24

  4. Number of Participants With Additional or Corrective Procedures Related to Total Joint Replacement Upto Week 24

    Participants were asked whether they had been told by their orthopedic surgeon that additional or corrective procedures were necessary for their total joint replacement. Participants, who responded as yes have been reported here. Participants may have been counted more than once if they had TJR surgery in more than one joint.

    Time frame: Baseline up to Week 24

  5. Number of Participants Who Participated in Physical Rehabilitation Activities Related to Total Joint Replacement Upto Week 24

    Participants responded with a yes or no to the following question ''are you participating in physical rehabilitation activities related to your replaced joint''. Participants responded with a yes, have been reported here. Participants may have been counted more than once if they had TJR surgery in more than one joint.

    Time frame: Baseline up to Week 24

  6. Change From Baseline in Average Pain Score in to be Replaced or Replaced Joints at Week 24

    Participants assessed their average pain in to be replaced (pre-surgery) knee/ hip joint or in the replaced joint (post-surgery) in the past 24 hours using an 11-point numerical rating scale (NRS), ranging from 0 (no pain) to 10 (worst possible pain). Higher scores indicated higher pain. Change from baseline was calculated using the difference between post-baseline weekly mean and the baseline mean score. Participants may have been counted more than once if they had TJR surgery in more than one joint.

    Time frame: Baseline, Week 24

  7. Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale at Week 24

    WOMAC: Self-administered, disease-specific questionnaire, which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis (OA). The WOMAC pain subscale is a 5-item questionnaire used to assess the amount of pain experienced due to OA of to be replaced/replaced index joint (knee or hip) during past 48 hours. It was calculated as the mean of scores from 5 individual questions. Scores for each question and WOMAC Pain subscale score on NRS ranged from 0 (no pain) to 10 (extreme pain), where higher scores indicated higher pain. Change from baseline was calculated using the difference between post-baseline weekly mean and the baseline mean score. Participants may have been counted more than once if they had TJR surgery in more than one joint.

    Time frame: Baseline, Week 24

  8. Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Stiffness Subscale at Week 24

    WOMAC: self-administered, disease-specific questionnaire, which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with OA. Stiffness was defined as a sensation of decreased ease of movement in the index joint (knee or hip). The WOMAC stiffness subscale is a 2-item questionnaire used to assess the amount of stiffness experienced due to OA in the replaced/to be replaced index joint (knee or hip) during the past 48 hours. It was calculated as the mean of scores from 2 individual questions scored on NRS. Scores for each question and WOMAC stiffness subscale score on NRS ranged from 0 (no stiffness) to 10 (extreme stiffness), where higher scores indicated higher stiffness. Change from baseline was calculated using the difference between post-baseline weekly mean and the baseline mean score. Participants may have been counted more than once if they had TJR surgery in more than one joint.

    Time frame: Baseline, Week 24

  9. Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function Subscale at Week 24

    WOMAC: Self-administered, disease-specific questionnaire, which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with OA. Physical function refers to participant's ability to move around and perform usual activities of daily living. The WOMAC physical function subscale is a 17-item questionnaire used to assess the degree of difficulty experienced due to OA in replaced/ to be replaced index joint (knee or hip) during past 48 hours. It was calculated as mean of the scores from 17 individual questions, which may not be a whole (integer) number, scored on a NRS. Scores for each question and WOMAC physical function subscale score on NRS ranged from 0 (no difficulty) to 10 (extreme difficulty), where higher scores indicated extreme difficulty/worse physical function. Participants may have been counted more than once if they had TJR surgery in more than one joint.

    Time frame: Baseline, Week 24

  10. Change From Baseline in Shoulder Pain and Disability Index (SPADI) Score at Week 24

    SPADI: self-administered questionnaire to measure pain and disability associated with shoulder pathology in participants with shoulder pain. It consists of two dimensions pain and function. Pain dimension:5 questions regarding severity of pain, scores ranged from 0=no pain to 10=worst pain imaginable, higher scores indicated extreme pain. Functional activities:8 questions to measure degree of difficulty with various activities of daily living that require upper extremity use, scores ranged from 0=no difficulty to 10=so difficult it requires help, higher scores=extreme difficulty. Pain and disability dimension score was calculated as the sum of non-missing scores divided by the maximum possible score (50 \[for pain\] and 80 \[for disability\]) multiplied by 100. A total score was calculated as the mean of two dimensions, ranged from 0=best to 100=worst, higher scores indicated worsening of condition.

    Time frame: Baseline, Week 24

  11. Number of Participants Who Used Concomitant Analgesic Medications

    Time frame: Baseline up to Week 24

07

Results

Posted Jul 30, 2020

Participant flow

This study included participants from studies A4091056 (NCT02697773), A4091057 (NCT02709486) and A4091058 (NCT02528188) who had undergone a total joint replacement (TJR) surgery of knee, hip, or shoulder. During this study, if participant underwent an additional TJR surgery, then data for that additional TJR surgery was also assessed.

Participant flow — Overall Study
MilestonePlaceboTanezumab CombinedNSAID
Started2011717
Safety analysis set2011317
Completed2010716
Not completed0101
Withdrew: Lost to follow-up011
Withdrew: Withdrawal by subject040
Withdrew: Other010
Withdrew: Enrolled but not evaluated040

Outcome measures

PrimaryNumber of Participants With Surgeon's Assessment of Procedural Difficulty

Following the TJR surgery on Day 1, the orthopedic surgeon was asked to answer the following question: "taking into consideration the participant's medical history and physical condition prior to surgery would you classify the operative procedure as Uneventful, Minor complications or Major complications." Participants were reported based on these categories for knee, hip and shoulder joint. Participants may have been counted more than once if they had TJR surgery in more than one joint.

Time frame:
Day 1
Reported as:
Count of participants · Participants
Number of Participants With Surgeon's Assessment of Procedural Difficulty
ParticipantsPlaceboTanezumab CombinedNSAIDAll Participants
Knee — Uneventful949866
Knee — Minor Complications0202
Knee — Major Complications0000
Hip — Uneventful837449
Hip — Minor Complications0404
Hip — Major Complications0000
Shoulder — Uneventful0011
Shoulder — Minor Complications0000
Shoulder — Major Complications0000
PrimaryNumber of Participants With Overall Satisfaction With Surgery as Assessed by the Self-Administered Patient Satisfaction (SAPS) Scale at Week 24

SAPS contained four questions; How satisfied are you with the 1) results of your surgery 2) results of surgery for improving pain 3) results of surgery for improving ability to do home or yard work, and 4) results of surgery for improving your ability to do recreational activities. Items scored on a 4-point Likert scale with response of 'very satisfied' (100 points), 'somewhat satisfied' (75 points), 'somewhat dissatisfied' (50 points), and 'very dissatisfied' (25 points). The scale score calculated as mean of the scores of individual items, ranging from 25 to 100, with higher scores indicating greater satisfaction. Here, number of participants are summarized as, satisfied (very satisfied and somewhat satisfied categories combined) and dissatisfied (somewhat dissatisfied and very dissatisfied categories combined). Participants may have been counted more than once if they had TJR surgery in more than one joint.

Time frame:
Week 24
Reported as:
Count of participants · Participants
Number of Participants With Overall Satisfaction With Surgery as Assessed by the Self-Administered Patient Satisfaction (SAPS) Scale at Week 24
ParticipantsPlaceboTanezumab CombinedNSAIDAll Participants
Knee: Satisfaction with result of surgery — Satisfied953567
Knee: Satisfaction with result of surgery — Dissatisfied0516
Knee: Results of surgery for relieving pain — Satisfied952566
Knee: Results of surgery for relieving pain — Dissatisfied0617
Knee: Improving ability for home or yard work — Satisfied948562
Knee: Improving ability for home or yard work — Dissatisfied010111
Knee: Improving ability-recreational activities — Satisfied950564
Knee: Improving ability-recreational activities — Dissatisfied0819
Hip: Satisfaction with result of surgery — Satisfied940655
Hip: Satisfaction with result of surgery — Dissatisfied1102
Hip: Results of surgery for relieving pain — Satisfied941656
Hip: Results of surgery for relieving pain — Dissatisfied1001
Hip: Improving ability for home or yard work — Satisfied941656
Hip: Improving ability for home or yard work — Dissatisfied1001
Hip: Improving ability-recreational activities — Satisfied940655
Hip: Improving ability-recreational activities — Dissatisfied1102
Shoulder: Satisfaction with result of surgery — Satisfied0011
Shoulder: Satisfaction with result of surgery — Dissatisfied0000
Shoulder: Results of surgery for relieving pain — Satisfied0011
Shoulder: Results of surgery for relieving pain — Dissatisfied0000
Shoulder: Improving ability for home or yard work — Satisfied0011
Shoulder: Improving ability for home or yard work — Dissatisfied0000
Shoulder:Improving ability-recreational activities — Satisfied0011
Shoulder:Improving ability-recreational activities — Dissatisfied0000
PrimaryNumber of Participants With Post-Surgical Complications Upto Week 24

Post-surgical complications are adverse events occurring after TJR surgery that were considered clinically significant as assessed by investigator and attributable to the total joint replacement procedure. Participants may have been counted more than once if they had TJR surgery in more than one joint.

Time frame:
Baseline up to Week 24
Reported as:
Count of participants · Participants
Number of Participants With Post-Surgical Complications Upto Week 24
ParticipantsPlaceboTanezumab CombinedNSAIDAll Participants
Knee0101
Hip0505
Shoulder0000
PrimaryNumber of Participants With Additional or Corrective Procedures Related to Total Joint Replacement Upto Week 24

Participants were asked whether they had been told by their orthopedic surgeon that additional or corrective procedures were necessary for their total joint replacement. Participants, who responded as yes have been reported here. Participants may have been counted more than once if they had TJR surgery in more than one joint.

Time frame:
Baseline up to Week 24
Reported as:
Count of participants · Participants
Number of Participants With Additional or Corrective Procedures Related to Total Joint Replacement Upto Week 24
ParticipantsPlaceboTanezumab CombinedNSAIDAll Participants
Knee0404
Hip0516
Shoulder0000
PrimaryNumber of Participants Who Participated in Physical Rehabilitation Activities Related to Total Joint Replacement Upto Week 24

Participants responded with a yes or no to the following question ''are you participating in physical rehabilitation activities related to your replaced joint''. Participants responded with a yes, have been reported here. Participants may have been counted more than once if they had TJR surgery in more than one joint.

Time frame:
Baseline up to Week 24
Reported as:
Count of participants · Participants
Number of Participants Who Participated in Physical Rehabilitation Activities Related to Total Joint Replacement Upto Week 24
ParticipantsPlaceboTanezumab CombinedNSAIDAll Participants
Knee1055772
Hip933345
Shoulder0011
PrimaryChange From Baseline in Average Pain Score in to be Replaced or Replaced Joints at Week 24

Participants assessed their average pain in to be replaced (pre-surgery) knee/ hip joint or in the replaced joint (post-surgery) in the past 24 hours using an 11-point numerical rating scale (NRS), ranging from 0 (no pain) to 10 (worst possible pain). Higher scores indicated higher pain. Change from baseline was calculated using the difference between post-baseline weekly mean and the baseline mean score. Participants may have been counted more than once if they had TJR surgery in more than one joint.

Time frame:
Baseline, Week 24
Reported as:
Mean · units on a scale
Change From Baseline in Average Pain Score in to be Replaced or Replaced Joints at Week 24
units on a scalePlaceboTanezumab CombinedNSAIDAll Participants
Baseline: Knee6.00 ± 2.316.86 ± 2.146.80 ± 2.206.76 ± 2.16
Baseline: Hip6.10 ± 2.136.81 ± 2.275.86 ± 3.446.60 ± 2.38
Change at Week 24: Knee-4.56 ± 1.24-5.32 ± 2.63-5.43 ± 2.51-5.24 ± 2.49
Change at Week 24: Hip-5.20 ± 2.30-5.67 ± 2.37-5.00 ± 4.10-5.52 ± 2.53
PrimaryChange From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale at Week 24

WOMAC: Self-administered, disease-specific questionnaire, which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis (OA). The WOMAC pain subscale is a 5-item questionnaire used to assess the amount of pain experienced due to OA of to be replaced/replaced index joint (knee or hip) during past 48 hours. It was calculated as the mean of scores from 5 individual questions. Scores for each question and WOMAC Pain subscale score on NRS ranged from 0 (no pain) to 10 (extreme pain), where higher scores indicated higher pain. Change from baseline was calculated using the difference between post-baseline weekly mean and the baseline mean score. Participants may have been counted more than once if they had TJR surgery in more than one joint.

Time frame:
Baseline, Week 24
Reported as:
Mean · units on a scale
Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale at Week 24
units on a scalePlaceboTanezumab CombinedNSAIDAll Participants
Baseline: Knee4.66 ± 3.055.62 ± 2.336.11 ± 2.315.56 ± 2.41
Baseline: Hip4.80 ± 2.615.97 ± 2.466.13 ± 1.985.80 ± 2.45
Change at Week 24: Knee-3.13 ± 1.74-4.50 ± 2.43-4.54 ± 3.15-4.34 ± 2.44
Change at Week 24: Hip-4.34 ± 2.52-4.92 ± 2.62-5.92 ± 2.40-4.91 ± 2.57
PrimaryChange From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Stiffness Subscale at Week 24

WOMAC: self-administered, disease-specific questionnaire, which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with OA. Stiffness was defined as a sensation of decreased ease of movement in the index joint (knee or hip). The WOMAC stiffness subscale is a 2-item questionnaire used to assess the amount of stiffness experienced due to OA in the replaced/to be replaced index joint (knee or hip) during the past 48 hours. It was calculated as the mean of scores from 2 individual questions scored on NRS. Scores for each question and WOMAC stiffness subscale score on NRS ranged from 0 (no stiffness) to 10 (extreme stiffness), where higher scores indicated higher stiffness. Change from baseline was calculated using the difference between post-baseline weekly mean and the baseline mean score. Participants may have been counted more than once if they had TJR surgery in more than one joint.

Time frame:
Baseline, Week 24
Reported as:
Mean · units on a scale
Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Stiffness Subscale at Week 24
units on a scalePlaceboTanezumab CombinedNSAIDAll Participants
Baseline: Knee4.80 ± 2.785.75 ± 2.526.44 ± 2.585.71 ± 2.55
Baseline: Hip4.70 ± 2.755.96 ± 2.695.25 ± 3.505.69 ± 2.77
Change at Week 24: Knee-1.78 ± 1.52-4.13 ± 2.58-3.43 ± 3.13-3.79 ± 2.62
Change at Week 24: Hip-4.00 ± 2.66-4.48 ± 2.87-3.80 ± 3.70-4.33 ± 2.86
PrimaryChange From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function Subscale at Week 24

WOMAC: Self-administered, disease-specific questionnaire, which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with OA. Physical function refers to participant's ability to move around and perform usual activities of daily living. The WOMAC physical function subscale is a 17-item questionnaire used to assess the degree of difficulty experienced due to OA in replaced/ to be replaced index joint (knee or hip) during past 48 hours. It was calculated as mean of the scores from 17 individual questions, which may not be a whole (integer) number, scored on a NRS. Scores for each question and WOMAC physical function subscale score on NRS ranged from 0 (no difficulty) to 10 (extreme difficulty), where higher scores indicated extreme difficulty/worse physical function. Participants may have been counted more than once if they had TJR surgery in more than one joint.

Time frame:
Baseline, Week 24
Reported as:
Mean · units on a scale
Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function Subscale at Week 24
units on a scalePlaceboTanezumab CombinedNSAIDAll Participants
Baseline: Knee4.83 ± 2.995.82 ± 2.116.63 ± 1.985.79 ± 2.23
Baseline: Hip5.56 ± 2.216.50 ± 2.226.86 ± 1.486.38 ± 2.17
Change at Week 24: Knee-2.69 ± 1.51-4.42 ± 2.19-4.59 ± 2.90-4.24 ± 2.24
Change at Week 24: Hip-4.64 ± 2.13-5.05 ± 2.44-5.95 ± 1.84-5.06 ± 2.33
PrimaryChange From Baseline in Shoulder Pain and Disability Index (SPADI) Score at Week 24

SPADI: self-administered questionnaire to measure pain and disability associated with shoulder pathology in participants with shoulder pain. It consists of two dimensions pain and function. Pain dimension:5 questions regarding severity of pain, scores ranged from 0=no pain to 10=worst pain imaginable, higher scores indicated extreme pain. Functional activities:8 questions to measure degree of difficulty with various activities of daily living that require upper extremity use, scores ranged from 0=no difficulty to 10=so difficult it requires help, higher scores=extreme difficulty. Pain and disability dimension score was calculated as the sum of non-missing scores divided by the maximum possible score (50 \[for pain\] and 80 \[for disability\]) multiplied by 100. A total score was calculated as the mean of two dimensions, ranged from 0=best to 100=worst, higher scores indicated worsening of condition.

Time frame:
Baseline, Week 24
Reported as:
Mean · units on a scale
Change From Baseline in Shoulder Pain and Disability Index (SPADI) Score at Week 24
units on a scalePlaceboTanezumab CombinedNSAIDAll Participants
Baseline——89.8889.88
Change at Week 24——-89.88-89.88
PrimaryNumber of Participants Who Used Concomitant Analgesic Medications
Time frame:
Baseline up to Week 24
Reported as:
Count of participants · Participants
Number of Participants Who Used Concomitant Analgesic Medications
ParticipantsPlaceboTanezumab CombinedNSAIDAll Participants
Number of Participants Who Used Concomitant Analgesic Medications1810015133

Adverse events

Collected over Baseline up to Week 24. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/20 (0%)0/20 (0%)0/20 (0%)
Tanezumab 2.5 mg0/52 (0%)5/52 (9.6%)9/52 (17.3%)
Tanezumab 2.5/5 mg0/8 (0%)3/8 (37.5%)3/8 (37.5%)
Tanezumab 5 mg0/53 (0%)7/53 (13.2%)9/53 (17%)
Tanezumab Combined0/113 (0%)15/113 (13.3%)21/113 (18.6%)
NSAID0/17 (0%)2/17 (11.8%)4/17 (23.5%)
All Participants0/150 (0%)17/150 (11.3%)25/150 (16.7%)
Most frequent serious events
Showing 10 of 19
Most frequent serious events
EventPlaceboTanezumab 2.5 mgTanezumab 2.5/5 mgTanezumab 5 mgTanezumab CombinedNSAIDAll Participants
Colitis ischaemicGastrointestinal disorders0/200/521/80/531/1130/171/150
Hiatus herniaGastrointestinal disorders0/200/521/80/531/1130/171/150
Gastroenteritis viralInfections and infestations0/200/521/80/531/1130/171/150
Transitional cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/200/521/80/531/1130/171/150
OsteoarthritisMusculoskeletal and connective tissue disorders0/201/520/82/533/1132/175/150
Coronary artery occlusionCardiac disorders0/201/520/80/531/1130/171/150
DiarrhoeaGastrointestinal disorders0/201/520/80/531/1130/171/150
EnteritisGastrointestinal disorders0/201/520/80/531/1130/171/150
Post procedural infectionInfections and infestations0/201/520/80/531/1130/171/150
Periprosthetic fractureInjury, poisoning and procedural complications0/201/520/80/531/1130/171/150
Most frequent other events
Showing 10 of 13
Most frequent other events
EventPlaceboTanezumab 2.5 mgTanezumab 2.5/5 mgTanezumab 5 mgTanezumab CombinedNSAIDAll Participants
ArthralgiaMusculoskeletal and connective tissue disorders0/200/521/82/533/1130/173/150
Spinal osteoarthritisMusculoskeletal and connective tissue disorders0/201/521/80/532/1130/172/150
Urinary retentionRenal and urinary disorders0/200/521/81/532/1130/172/150
Procedural painInjury, poisoning and procedural complications0/203/520/86/539/1130/179/150
Atrioventricular block second degreeCardiac disorders0/200/520/80/530/1131/171/150
Coronary artery stenosisCardiac disorders0/200/520/80/530/1131/171/150
Chest painGeneral disorders0/200/520/80/530/1131/171/150
Peripheral swellingGeneral disorders0/200/520/80/530/1131/171/150
Drug hypersensitivityImmune system disorders0/200/520/80/530/1131/171/150
Joint swellingMusculoskeletal and connective tissue disorders0/201/520/80/531/1131/172/150

Baseline characteristics

Safety analysis set: all enrolled participants of this study who had received at least one dose of SC study medication during studies A4091056, A4091057 or A4091058, and who had a qualifying i.e. total (not partial) joint replacement surgery.

Age, Continuous
Age, Continuous(Years)PlaceboTanezumab CombinedNSAIDTotal
Mean65.26 ± 8.7764.57 ± 8.1862.94 ± 9.1364.47 ± 8.33
Sex/Gender, Customized
Sex/Gender, Customized(Participants)PlaceboTanezumab CombinedNSAIDTotal
Male650460
Female13621388
Unspecified1102
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboTanezumab CombinedNSAIDTotal
Hispanic or Latino1337
Not Hispanic or Latino1810914141
Unknown or Not Reported1102
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboTanezumab CombinedNSAIDTotal
American Indian or Alaska Native0000
Asian2608
Native Hawaiian or Other Pacific Islander0000
Black or African American0639
White1710014131
More than one race0000
Unknown or Not Reported1102
08

Study locations

79 sites
  • Central Alabama Research
    Birmingham, Alabama 35209, United States
  • Alabama Clinical Therapeutics, LLC
    Birmingham, Alabama 35235, United States
  • Alabama Orthopaedic Surgeons
    Birmingham, Alabama 35235, United States
  • Cahaba Research Inc.
    Birmingham, Alabama 35242, United States
  • Noble Clinical Research
    Tucson, Arizona 85704, United States
  • Baptist Health Center for Clinical Research
    Little Rock, Arkansas 72205, United States
  • Advanced Research Center, Inc.
    Anaheim, California 92805, United States
  • Hope Clinical Research
    Canoga Park, California 91303, United States
  • Marvel Clinical Research, LLC
    Huntington Beach, California 92647, United States
  • Advances in Medicine
    Palm Desert, California 92260, United States
  • Clinical Trials Research
    Sacramento, California 95821, United States
  • California Research Foundation
    San Diego, California 92123, United States
  • CITrials
    Santa Ana, California 92705, United States
  • Stamford Therapeutics Consortium
    Stamford, Connecticut 06905, United States
  • JEM Research Institute
    Atlantis, Florida 33462, United States
  • Orthopedic Research Institute
    Boynton Beach, Florida 33472, United States
  • Orthopaedic Associates of West Florida
    Clearwater, Florida 33756, United States
  • Clinical Neuroscience Solutions, Inc.
    Jacksonville, Florida 32256, United States
  • Clintex Research Group
    Miami, Florida 33135, United States
  • Renstar Medical Research
    Ocala, Florida 34470, United States
  • American Family Medical
    Ocala, Florida 34471, United States
  • Sunshine Research Center
    Opa-locka, Florida 33054, United States
  • Gulfcoast Research Institute, LLC
    Sarasota, Florida 34232-6028, United States
  • Kennedy White Orthopaedic Center
    Sarasota, Florida 34232, United States
  • Stedman Clinical Trials
    Tampa, Florida 33613, United States
  • Masters of Clinical Research, Inc.
    Augusta, Georgia 30909, United States
  • North Georgia Clinical Research
    Woodstock, Georgia 30189, United States
  • North Georgia Internal Medicine
    Woodstock, Georgia 30189, United States
  • Injury Care Research
    Boise, Idaho 83713, United States
  • Chicago Clinical Research Institute, Inc.
    Chicago, Illinois 60607, United States
  • Northwestern University
    Chicago, Illinois 60611, United States
  • Professional Research Network of Kansas, LLC
    Wichita, Kansas 67205-1138, United States
  • Best Clinical Trials, LLC
    New Orleans, Louisiana 70115, United States
  • George Stanley Walker, MD
    New Orleans, Louisiana 70115, United States
  • Great Lakes Research Group, Incorporated
    Bay City, Michigan 48706, United States
  • Orthopaedic Associates of Michigan, PC
    Grand Rapids, Michigan 49525, United States
  • Physician Research Collaboration, LLC
    Lincoln, Nebraska 68516, United States
  • Drug Trials America
    Hartsdale, New York 10530, United States
  • Remington-Davis, Incorporated
    Columbus, Ohio 43215, United States
  • Optimed Research LTD
    Columbus, Ohio 43235, United States
  • AC Clinical Research
    Tiffin, Ohio 44883, United States
  • Founders Research Corporation
    Philadelphia, Pennsylvania 19114, United States
  • Abigail R. Neiman, MD, PA
    Houston, Texas 77024, United States
  • Advances In Health
    Houston, Texas 77030, United States
  • Mercury Clinical Research, Inc.
    Houston, Texas 77036, United States
  • BI Research Center
    Houston, Texas 77084, United States
  • ClinRx Research
    Richardson, Texas 75080, United States
  • DCT - Stone Oak, LLC dba Discovery Clinical Trials
    San Antonio, Texas 78258, United States
  • Mercury Clinical Research
    Webster, Texas 77598, United States
  • Spectrum Medical, Inc.
    Danville, Virginia 24541, United States
  • Northwest Clinical Research Center
    Bellevue, Washington 98007, United States
  • CMAX Clinical Research Pty Ltd
    Adelaide, South Australia 5000, Australia
  • Dawson Road Medical Centre
    Guelph, Ontario N1H 1B1, Canada
  • Rebecca Medical Associates
    Oakville, Ontario L6K 1J6, Canada
  • Recherche Clinique Sigma inc
    Quebec, G1G 3Y8, Canada
  • Centre de recherche Saint-Louis
    Quebec, G1W 4R4, Canada
  • Rheumazentrum Prof. Dr. med Gunther Neeck
    Bad Doberan, 18209, Germany
  • Tolna Megyei Balassa Janos Korhaz, Ortopediai Osztaly
    Szekszard, 7100, Hungary
  • Azienda Ospedaliero-Universitaria E Policlinico Umberto I
    Rome, 00161, Italy
  • Omuro Orthopedic Clinic
    Himeji, Hyogo 670-0976, Japan
  • Nakajo Orthopedic Clinic
    Sendai, Miyagi 983-0862, Japan
  • Marunouchi Hospital
    Matsumoto, Nagano 390-8601, Japan
  • National Hospital Organization Osaka Minami Medical Center
    Kawachinagano, Osaka 586-8521, Japan
  • Osaka University Hospital
    Suita, Osaka 565-0871, Japan
  • Saules seimos medicinos centras
    Kaunas, LT-49449, Lithuania
  • South Pacific Clinical Trials
    Auckland, 0610, New Zealand
  • Star Unit, North Shore Hospital, Waitemata District Health Board
    Auckland, 0622, New Zealand
  • Southern Clinical Trials- Waitemata Ltd
    Auckland, 0626, New Zealand
  • Clinical Horizons NZ Ltd
    Tauranga, 3112, New Zealand
  • Hospital Conde de Bertiandos
    Ponte de Lima, Viana DO Castelo 4990-041, Portugal
  • Medical Technologies Ltd.
    Saint-Petersburg, 191025, Russian Federation
  • Institute of Rheumatology
    Belgrade, 11000, Serbia
  • Kompan, s.r.o.
    Dolny Kubin, 02601, Slovakia
  • Slovak Research Center Team Member, MUDr. Viliam Cibik, PhD, s.r.o.
    Pruske, 018 52, Slovakia
  • Instituto de Ciencias Medicas
    Alicante, 03004, Spain
  • Hospital del Mar
    Barcelona, 08003, Spain
  • Ladulaas Kliniska Studier
    Boras, Sweden, SE-506 30, Sweden
  • ProbarE I Lund AB
    Lund, 222 22, Sweden
  • ProbarE i Stockholm AB
    Stockholm, 111 37, Sweden
09

References and documents

Publications

  • Mont MA, Carrino JA, Nemeth MA, Burr A, Yamabe T, Viktrup L, Brown MT, West CR, Verburg KM. Postoperative Outcome of Patients Who Underwent Total Joint Replacement During the Tanezumab Phase 3 Osteoarthritis Development Program: A 24-Week Observational Study. Surg Technol Int. 2021 May 20;38:467-477. doi: 10.52198/21.STI.38.OS1439. PubMed 34043229 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2016 to primary completion in Jul 2019, 34 months.

Results were first posted in Jul 2020, 1 year after primary completion.

Of 60 industry-sponsored phase 3 interventional studies under Osteoarthritis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 22. This study's 34 months is above that.

Counting every sponsor, half of 84 studies reached it within 17 months; a quarter within 11 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2015
First posted
Feb 4, 2016
StartActual
Aug 23, 2016
Primary completionActual
Jul 15, 2019
CompletionActual
Jul 15, 2019
Results first posted
Jul 30, 2020
Last update
Jul 30, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 30, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02674386
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Feb 4, 2016
Start date
Aug 23, 2016
Primary completion
Jul 15, 2019
Completion
Jul 15, 2019
Results posted
Jul 30, 2020
Last update
Jul 30, 2020

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Inosine Monophosphate

Start the discussion